-
1
-
-
0027417437
-
The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
-
8433390 10.1093/jnci/85.5.365 1:STN:280:DyaK3s7msVarsQ%3D%3D
-
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376
-
(1993)
J Natl Cancer Inst
, vol.85
, pp. 365-376
-
-
Aaronson, N.K.1
Ahmedzai, S.2
Bergman, B.3
Bullinger, M.4
Cull, A.5
Duez, N.J.6
Filiberti, A.7
Flechtner, H.8
Fleishman, S.B.9
De Haes, J.10
Kaasa, S.11
Klee, M.C.12
Osoba, D.13
Razavi, D.14
Rofe, P.B.15
Schraub, S.16
Sneeuw, K.C.A.17
Sullivan, M.18
Takeda, F.19
-
2
-
-
0036118502
-
Quality of life and tolerance of maintenance treatment in patients with multiple myeloma. [Czech]
-
Czech Myeloma Group 11968583 1:STN:280:DC%2BD383jtFSnsQ%3D%3D
-
Adam Z, Pour L, Svobodník A, Scudla V, Salajka F, Vytrasová M, Bacovský J, Schützová M, Koza V, Sumná E, Franková H, Lehanka F, Gumulec J, Stavarová Y, Cahová S, Vránová M, Dostálová V, Kessler P, Walterová L, Meluzínová I, Seifertová N, Sláma O, Büchler T, Krejcí M, Bencíková V, Nykodýmová V, Dusek L, Hájek R, Czech Myeloma Group (2002) Quality of life and tolerance of maintenance treatment in patients with multiple myeloma. [Czech]. Vnitr Lek 48:216-229
-
(2002)
Vnitr Lek
, vol.48
, pp. 216-229
-
-
Adam, Z.1
Pour, L.2
Svobodník, A.3
Scudla, V.4
Salajka, F.5
Vytrasová, M.6
Bacovský, J.7
Schützová, M.8
Koza, V.9
Sumná, E.10
Franková, H.11
Lehanka, F.12
Gumulec, J.13
Stavarová, Y.14
Cahová, S.15
Vránová, M.16
Dostálová, V.17
Kessler, P.18
Walterová, L.19
Meluzínová, I.20
Seifertová, N.21
Sláma, O.22
Büchler, T.23
Krejcí, M.24
Bencíková, V.25
Nykodýmová, V.26
Dusek, L.27
Hájek, R.28
more..
-
3
-
-
79958846304
-
Guidelines for the diagnosis and management of multiple myeloma 2011
-
Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum 21569004 10.1111/j.1365-2141.2011.08573. x 1:CAS:528:DC%2BC3MXpsFWis7k%3D
-
Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J, Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154:32-75
-
(2011)
Br J Haematol
, vol.154
, pp. 32-75
-
-
Bird, J.M.1
Owen, R.G.2
D'Sa, S.3
Snowden, J.A.4
Pratt, G.5
Ashcroft, J.6
Yong, K.7
Cook, G.8
Feyler, S.9
Davies, F.10
Morgan, G.11
Cavenagh, J.12
Low, E.13
Behrens, J.14
-
5
-
-
84874112593
-
-
Cancer Research UK Accessed 20 Dec 2010
-
Cancer Research UK (2007) http://www.cancerresearchuk.org/. Accessed 20 Dec 2010
-
(2007)
-
-
-
6
-
-
34447266200
-
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
-
EORTC Quality of Life Group 17574838 10.1016/j.ejca.2007.04.022 1:STN:280:DC%2BD2svhtFelsQ%3D%3D
-
Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J, EORTC Quality of Life Group (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43:1670-1678
-
(2007)
Eur J Cancer
, vol.43
, pp. 1670-1678
-
-
Cocks, K.1
Cohen, D.2
Wisløff, F.3
Sezer, O.4
Lee, S.5
Hippe, E.6
Gimsing, P.7
Turesson, I.8
Hajek, R.9
Smith, A.10
Graham, L.11
Phillips, A.12
Stead, M.13
Velikova, G.14
Brown, J.15
-
7
-
-
36349023319
-
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
-
Multiple Myeloma (010) Study Investigators 18032762 10.1056/NEJMoa070594 1:CAS:528:DC%2BD2sXhtlGis7nN
-
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellman A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple Myeloma (010) Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123-2132
-
(2007)
N Engl J Med
, vol.357
, pp. 2123-2132
-
-
Dimopoulos, M.1
Spencer, A.2
Attal, M.3
Prince, H.M.4
Harousseau, J.L.5
Dmoszynska, A.6
San Miguel, J.7
Hellman, A.8
Facon, T.9
Foà, R.10
Corso, A.11
Masliak, Z.12
Olesnyckj, M.13
Yu, Z.14
Patin, J.15
Zeldis, J.B.16
Knight, R.D.17
-
8
-
-
0031279593
-
Modelling valuations for EuroQol Health States
-
9366889 10.1097/00005650-199711000-00002 1:STN:280:DyaK1c%2FjtlKrtg%3D%3D
-
Dolan P (1997) Modelling valuations for EuroQol Health States. Med Care 35:1095-1108
-
(1997)
Med Care
, vol.35
, pp. 1095-1108
-
-
Dolan, P.1
-
9
-
-
33644885460
-
Descriptive and prognostic value of patient-reported outcomes: The bortezomib experience in relapsed and refractory multiple myeloma
-
16432077 10.1200/JCO.2005.04.0824 1:CAS:528:DC%2BD28Xitl2qt7k%3D
-
Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, de la Loge C (2006) Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 24:976-982
-
(2006)
J Clin Oncol
, vol.24
, pp. 976-982
-
-
Dubois, D.1
Dhawan, R.2
Van De Velde, H.3
Esseltine, D.4
Gupta, S.5
Viala, M.6
De La Loge, C.7
-
10
-
-
0025688231
-
EuroQol - A new facility for the measurement of health-related quality of life
-
EuroQol Group 10.1016/0168-8510(90)90421-9
-
EuroQol Group (1990) EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
-
(1990)
Health Policy
, vol.16
, pp. 199-208
-
-
-
11
-
-
34848833957
-
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial
-
17920916 10.1016/S0140-6736(07)61537-2 1:CAS:528:DC%2BD2sXhtFehsr%2FN
-
Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370:1209-1218
-
(2007)
Lancet
, vol.370
, pp. 1209-1218
-
-
Facon, T.1
Mary, J.Y.2
Hulin, C.3
Benboubker, L.4
Attal, M.5
Pegourie, B.6
Renaud, M.7
Harousseau, J.L.8
Guillerm, G.9
Chaleteix, C.10
Dib, M.11
Voillat, L.12
Maisonneuve, H.13
Troncy, J.14
Dorvaux, V.15
Monconduit, M.16
Martin, C.17
Casassus, P.18
Jaubert, J.19
Jardel, H.20
Doyen, C.21
Kolb, B.22
Anglaret, B.23
Grosbois, B.24
Yakoub-Agha, I.25
Mathiot, C.26
Avet-Loiseau, H.27
more..
-
12
-
-
0003915551
-
-
EORTC Quality of Life Study Group 3 EORTC Quality of Life Group Brussels
-
Fayers P, Aaronson NK, Bjordal K, Curran D, Groenvold M, EORTC Quality of Life Study Group (2001) EORTC QLQ-C30 scoring manual, 3rd edn. EORTC Quality of Life Group, Brussels
-
(2001)
EORTC QLQ-C30 Scoring Manual
-
-
Fayers, P.1
Aaronson, N.K.2
Bjordal, K.3
Curran, D.4
Groenvold, M.5
-
13
-
-
17944365031
-
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support
-
Nordic Myeloma Study Group 11778972 10.1385/MO:18:1:65 1:CAS:528:DC%2BD38XmtF2hs7w%3D
-
Gulbrandsen N, Wisløff F, Brinch L, Carlson K, Dahl IM, Gimsing P, Hippe E, Hjorth M, Knudsen LM, Lamvik J, Lenhoff S, Lofvenberg E, Nesthus I, Nielsen JL, Turesson I, Westin J, Nordic Myeloma Study Group (2001) Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 18:65-77
-
(2001)
Med Oncol
, vol.18
, pp. 65-77
-
-
Gulbrandsen, N.1
Wisløff, F.2
Brinch, L.3
Carlson, K.4
Dahl, I.M.5
Gimsing, P.6
Hippe, E.7
Hjorth, M.8
Knudsen, L.M.9
Lamvik, J.10
Lenhoff, S.11
Lofvenberg, E.12
Nesthus, I.13
Nielsen, J.L.14
Turesson, I.15
Westin, J.16
-
14
-
-
68949137225
-
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
-
19451428 10.1200/JCO.2008.21.0948 1:CAS:528:DC%2BD1MXhtVOnu7bJ
-
Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azais I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27:3664-3670
-
(2009)
J Clin Oncol
, vol.27
, pp. 3664-3670
-
-
Hulin, C.1
Facon, T.2
Rodon, P.3
Pegourie, B.4
Benboubker, L.5
Doyen, C.6
Dib, M.7
Guillerm, G.8
Salles, B.9
Eschard, J.P.10
Lenain, P.11
Casassus, P.12
Azais, I.13
Decaux, O.14
Garderet, L.15
Mathiot, C.16
Fontan, J.17
Lafon, I.18
Virion, J.M.19
Moreau, P.20
more..
-
15
-
-
0003068836
-
The EuroQoL instrument: An index of health-related quality of life
-
Spilker (eds) 2 Lippincott-Raven Philadelphia
-
Kind P (1996) The EuroQoL instrument: An index of health-related quality of life. In: Spilker (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven, Philadelphia
-
(1996)
Quality of Life and Pharmacoeconomics in Clinical Trials
-
-
Kind, P.1
-
16
-
-
41949130070
-
Improved survival in multiple myeloma and the impact of novel therapies
-
17975015 10.1182/blood-2007-10-116129 1:CAS:528:DC%2BD1cXivFaktrk%3D
-
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520
-
(2008)
Blood
, vol.111
, pp. 2516-2520
-
-
Kumar, S.K.1
Rajkumar, S.V.2
Dispenzieri, A.3
Lacy, M.Q.4
Hayman, S.R.5
Buadi, F.K.6
Zeldenrust, S.R.7
Dingli, D.8
Russell, S.J.9
Lust, J.A.10
Greipp, P.R.11
Kyle, R.A.12
Gertz, M.A.13
-
17
-
-
70349126639
-
Health-related quality of life assessment in randomised controlled trials in multiple myeloma: A critical review of methodology and impact on treatment recommendations
-
19558508 10.1111/j.1600-0609.2009.01303.x
-
Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F (2009) Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol 83:279-289
-
(2009)
Eur J Haematol
, vol.83
, pp. 279-289
-
-
Kvam, A.K.1
Fayers, P.2
Hjermstad, M.3
Gulbrandsen, N.4
Wisloff, F.5
-
18
-
-
54849424765
-
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: Results from the APEX study
-
18986387 1:CAS:528:DC%2BD1MXms1Wj
-
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC (2008) Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 143:511-519
-
(2008)
Br J Haematol
, vol.143
, pp. 511-519
-
-
Lee, S.J.1
Richardson, P.G.2
Sonneveld, P.3
Schuster, M.W.4
Irwin, D.5
San Miguel, J.F.6
Crawford, B.7
Massaro, J.8
Dhawan, R.9
Gupta, S.10
Anderson, K.C.11
-
19
-
-
33644843725
-
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomized controlled trial
-
16530576 10.1016/S0140-6736(06)68338-4 1:CAS:528:DC%2BD28Xit1eht7c%3D
-
Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M, Italian Multiple Myeloma Network GIMEMA (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 367:825-831
-
(2006)
Lancet
, vol.367
, pp. 825-831
-
-
Palumbo, A.1
Bringhen, S.2
Caravita, T.3
Merla, E.4
Capparella, V.5
Callea, V.6
Cangialosi, C.7
Grasso, M.8
Rossini, F.9
Galli, M.10
Catalano, L.11
Zamagni, E.12
Petrucci, M.T.13
De Stefano, V.14
Ceccarelli, M.15
Ambrosini, M.T.16
Avonto, I.17
Falco, P.18
Ciccone, G.19
Liberati, A.M.20
Musto, P.21
Boccadoro, M.22
more..
-
20
-
-
70350094381
-
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
-
IMWG 19494840 10.1038/leu.2009.122 1:STN:280:DC%2BD1Mnos12jtA%3D%3D
-
Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KS, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S, IMWG (2009) International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23:1716-1730
-
(2009)
Leukemia
, vol.23
, pp. 1716-1730
-
-
Palumbo, A.1
Sezer, O.2
Kyle, R.3
Miguel, J.S.4
Orlowski, R.Z.5
Moreau, P.6
Niesvizky, R.7
Morgan, G.8
Comenzo, R.9
Sonneveld, P.10
Kumar, S.11
Hajek, R.12
Giralt, S.13
Bringhen, S.14
Anderson, K.S.15
Richardson, P.G.16
Cavo, M.17
Davies, F.18
Bladé, J.19
Einsele, H.20
Dimopoulos, M.A.21
Spencer, A.22
Dispenzieri, A.23
Reiman, T.24
Shimizu, K.25
Lee, J.H.26
Attal, M.27
Boccadoro, M.28
Mateos, M.29
Chen, W.30
Ludwig, H.31
Joshua, D.32
Chim, J.33
Hungria, V.34
Turesson, I.35
Durie, B.G.36
Lonial, S.37
more..
-
21
-
-
20444433230
-
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
-
Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators 15958804 10.1056/NEJMoa043445 1:CAS:528:DC%2BD2MXltlaksLc%3D
-
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498
-
(2005)
N Engl J Med
, vol.352
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.W.3
Irwin, D.4
Stadtmauer, E.A.5
Facon, T.6
Harousseau, J.L.7
Ben-Yehuda, D.8
Lonial, S.9
Goldschmidt, H.10
Reece, D.11
San-Miguel, J.F.12
Bladé, J.13
Boccadoro, M.14
Cavenagh, J.15
Dalton, W.S.16
Boral, A.L.17
Esseltine, D.L.18
Porter, J.B.19
Schenkein, D.20
Anderson, K.C.21
more..
-
22
-
-
79955016800
-
Evidence-based mini-review: Treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation
-
American Society of Hematology. Education Program, 2010
-
Shah N, Lonial S (2010) Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2010: 310-313
-
(2010)
Hematology/the Education Program of the American Society of Hematology
, pp. 310-313
-
-
Shah, N.1
Lonial, S.2
-
23
-
-
0030945323
-
ABC of clinical haematology. Multiple myeloma and related conditions
-
9099124 10.1136/bmj.314.7085.960 1:STN:280:DyaK2s3ltlyrtA%3D%3D
-
Singer CR (1997) ABC of clinical haematology. Multiple myeloma and related conditions. BMJ 314:960-963
-
(1997)
BMJ
, vol.314
, pp. 960-963
-
-
Singer, C.R.1
-
24
-
-
1642374858
-
Multiple myeloma
-
15031034 10.1016/S0140-6736(04)15736-X
-
Sirohi B, Powles R (2004) Multiple myeloma. Lancet 363:875-887
-
(2004)
Lancet
, vol.363
, pp. 875-887
-
-
Sirohi, B.1
Powles, R.2
-
25
-
-
0032988090
-
Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European organization for research and treatment of cancer study group on quality of life
-
10086801 10.1046/j.1365-2141.1999.01206.x 1:STN:280:DyaK1M7osVKjtw%3D%3D
-
Stead ML, Brown JM, Velikova G, Kaasa S, Wisløff F, Child JA, Hippe E, Hjorth M, Sezer O, Selby P (1999) Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European organization for research and treatment of cancer study group on quality of life. Br J Haematol 104:605-611
-
(1999)
Br J Haematol
, vol.104
, pp. 605-611
-
-
Stead, M.L.1
Brown, J.M.2
Velikova, G.3
Kaasa, S.4
Wisløff, F.5
Child, J.A.6
Hippe, E.7
Hjorth, M.8
Sezer, O.9
Selby, P.10
-
26
-
-
1942424107
-
A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; A prospective randomised phase III study
-
15110879
-
van Agthoven M, Segeren CM, Buijt I, Uyl-De Groot CA, van der Holt B, Lokhorst HM, Sonneveld P (2004) A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer 40:1159-1169
-
(2004)
Eur J Cancer
, vol.40
, pp. 1159-1169
-
-
Van Agthoven, M.1
Segeren, C.M.2
Buijt, I.3
Uyl-De Groot, C.A.4
Van Der Holt, B.5
Lokhorst, H.M.6
Sonneveld, P.7
-
27
-
-
77956599686
-
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
-
Nordic Myeloma Study Group 10.1182/blood-2009-08-237974 20448107 10.1182/blood-2009-08-237974 1:CAS:528:DC%2BC3cXhtF2qsb%2FM
-
Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I, Nordic Myeloma Study Group (2010) Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116:1405-1412. doi: 10.1182/blood-2009-08-237974
-
(2010)
Blood
, vol.116
, pp. 1405-1412
-
-
Waage, A.1
Gimsing, P.2
Fayers, P.3
Abildgaard, N.4
Ahlberg, L.5
Björkstrand, B.6
Carlson, K.7
Dahl, I.M.8
Forsberg, K.9
Gulbrandsen, N.10
Haukås, E.11
Hjertner, O.12
Hjorth, M.13
Karlsson, T.14
Knudsen, L.M.15
Nielsen, J.L.16
Linder, O.17
Mellqvist, U.H.18
Nesthus, I.19
Rolke, J.20
Strandberg, M.21
Sørbø, J.H.22
Wisløff, F.23
Juliusson, G.24
Turesson, I.25
more..
-
28
-
-
77955495783
-
Phase III study of the value of thalidomide added to melphalan plus prednisolone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 study
-
Dutch-Belgium Cooperative Group HOVON 10.1200/JCO.2009.26.1610 20516439 10.1200/JCO.2009.26.1610 1:CAS:528:DC%2BC3cXpslajtL8%3D
-
Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst H, Sonneveld P, Dutch-Belgium Cooperative Group HOVON (2010) Phase III study of the value of thalidomide added to melphalan plus prednisolone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J Clin Oncol 28:3160-3166. doi: 10.1200/JCO.2009.26.1610
-
(2010)
J Clin Oncol
, vol.28
, pp. 3160-3166
-
-
Wijermans, P.1
Schaafsma, M.2
Termorshuizen, F.3
Ammerlaan, R.4
Wittebol, S.5
Sinnige, H.6
Zweegman, S.7
Van Marwijk Kooy, M.8
Van Der Griend, R.9
Lokhorst, H.10
Sonneveld, P.11
|